Open AccessTHE SAFETY OF MESENCHIMAL STROMAL CELLS THERAPY
Author(s) -
Oleg Knyazev,
Князев Олег Владимирович,
A.G. Konoplyannikov,
Коноплянников Анатолий Георгиевич,
А И Парфенов,
Парфенов Асфольд Иванович,
И Н Ручкина,
И Н Ручкина,
А. А. Чурикова,
Чурикова Алевтина Алексеевна,
Е А Албулова,
Е А Албулова,
С В Быкова,
С В Быкова,
О Н Болдырева,
О Н Болдырева,
Н А Фадеева,
Фадеева Нина Александровна,
A A Lishinskaya,
Лищинская Альбина Александровна,
E Yu Bondarenko,
Бондаренко Елена Юрьевна,
A Kagramanova,
Каграманова Анна Валерьевна
Publication year - 2014
Publication title -
kliničeskaâ praktika
Language(s) - English
Resource type - Journals
eISSN - 2618-8627
pISSN - 2220-3095
DOI - 10.17816/clinpract535-14
Subject(s) - mesenchymal stem cell , medicine , immunogenicity , stromal cell , clinical trial , inflammatory bowel disease , intensive care medicine , cell therapy , clinical practice , disease , immunology , pathology , cell , immune system , physical therapy , biology , genetics
There is a large amount of literature data that shows the effectiveness of cell therapy using mesenchymal stromal cells (MSCs), as on preclinical models and in some clinical studies in small groups of patients.Currently the use of MSC in clinical practice is limited by security considerations. Potential risks associated with their proliferative capacity, the risk of infectious complications, as well as the possible immunogenicity of the cells themselves.Foreign researchers analyzed on the basis of a literature review, the results of which evaluated the clinical safety of MSCs. The article presents the results of our monitoring of patients with inflammatory bowel disease (IBD), which received MSCs in the Department of pathology bowel. The results of our study, and the results, given in the review, should provide scientists and policy-makers the confidence that according to available scientific data an innovative method of cell therapy is safe for clinical use.